Home / Research library / Cagrilintide
Compound guide
Cagrilintide: what the research covers
An amylin analogue, not an incretin. It reaches appetite regulation through a receptor family entirely separate from the GLP-1 system, which is why the two are studied together.
What Cagrilintide is
Amylin is a thirty-seven residue peptide co-secreted with insulin from pancreatic beta cells, and it signals satiety, slows gastric emptying and suppresses glucagon. Native human amylin has a serious practical problem: it aggregates into amyloid fibrils, which is both a formulation obstacle and a feature of the pathology in type 2 diabetes.
Cagrilintide is an engineered amylin analogue with substitutions that suppress that aggregation, plus a fatty acid chain that binds albumin and extends its circulating life from minutes to a scale measured in days. It acts at the calcitonin receptor and at amylin receptors formed when that receptor associates with receptor activity-modifying proteins.
The important point for study design is that this is not an incretin pathway. GLP-1 receptor agonists and amylin analogues both reduce food intake, and they do it through different receptors in different nuclei of the hindbrain.
Why it is studied in combination
Two independent appetite pathways invite the obvious experiment, and the published work follows it: amylin analogue alone, incretin agonist alone, and both together, with the question being whether the effects are additive. The clinical programme pairing cagrilintide with semaglutide is the most prominent example and reported effects larger than either component produced on its own.
That is interesting mechanistically rather than merely commercially, because additivity implies the two pathways converge downstream rather than duplicating each other. It also makes cagrilintide a useful tool for anyone trying to establish whether an observed effect in a combination preparation belongs to the incretin arm or the amylin arm — a question that cannot be answered without the single agents.
Research strands cover receptor pharmacology at the calcitonin and amylin receptor complexes, aggregation behaviour of engineered analogues, hindbrain satiety circuitry, and gastric emptying.
How Amino Club supplies it
Supplied lyophilised in sealed vials as Cagrilintide, and in a combined preparation as Cagrilintide + Semaglutide. Each is released against the Certificate of Analysis for its own batch; the lab testing page documents the release sequence.
Acylated peptides of this length behave more like proteins than like short peptides in handling terms: they are surface active, so vigorous agitation should be avoided, and the fatty acid chain makes concentration-dependent self-association a real consideration when preparing stock solutions. The sealed powder is stored below −18 °C and solutions kept cold and used promptly. Diluents are under reconstitution supplies.
Related reading
Cagrilintide sits in the metabolic research peptides group with mazdutide, survodutide, AOD-9604, 5-Amino-1MQ and AICAR. The hub page sets out how that group divides by mechanism.
Every guide is indexed in the research library. Certificates and storage are covered on the FAQ, quantity pricing through bulk and wholesale.
Research use only
Cagrilintide supplied by Amino Club is a laboratory reference material. It is not a medicine, not a supplement, and not for human or veterinary use, and no dosing guidance or administration protocol is provided. The full terms are in the research use policy.